Recently, new and less invasive protocols for CXL treatment have been proposed. Accelerated CXL uses higher irradiances (9 or 18 mW/cm²) and is applied to reduce the irradiation time (10 or 5 min, respectively). Transepithelial CXL [17] does not require de-epithelialization due to the aggregation of benzalconium chloride or ethylenediaminetetraacetic acid (EDTA) to the riboflavin solution. Additionally, the riboflavin diffusion speed into the corneal stroma can be increased by iontophoresis [18]. Transepithelial treatment is less painful and increases the speed of postoperative wound healing. There are several studies that suggest accelerated CXL [19, 20], transepithelial CXL without [21, 22] or with iontophoresis [23] is effective in pediatric patients. Others in contrast reported that transepithelial CXL did not stop pediatric keratoconus progression [24]. There is ongoing research performed to develop faster and more comfortable treatment protocols. However, current laboratory studies suggest that standard CXL is most effective in terms of biomechanical stiffness increase [15]. Therefore, the authors suggest to use the Geneva protocol as a tool in the decision-making process for cross-linking procedures.